Recent Company News

• 01:52 AM ET Nov 06, 2025
  

  Santen Pharmaceutical completes ¥31.9B buyback (¥1499.5000, 0)

• 01:46 AM ET Nov 06, 2025
  

  Santen Pharmaceutical reports Q2 core net income ¥9.84B vs FactSet ¥7.78B (¥1499.5000, 0)

• 09:40 AM ET Nov 05, 2025
  

  Santen announces UK approves Ryjunea to slow progression of childhood myopia (¥1518.5000, 0)

• 02:54 PM ET Oct 01, 2025
  

  Santen Pharmaceutical repurchased 2.8M shares during September (¥1642.0000, 0)

• 01:03 PM ET Sep 26, 2025
  

  StreetAccount Activist Summary: Week of 22-Sep

• 02:05 AM ET Sep 22, 2025
  

  Santen Pharmaceutical holder Silchester International Investors raises stake to 7.10% from (¥1655.0000, +5)

• 08:05 AM ET Sep 18, 2025
  

  Kairos Pharma announces positive interim efficacy analysis of phase 2 trial of ENV105 ($1.68, 0.00)

• 10:33 PM ET Aug 07, 2025
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 07:26 PM ET Aug 07, 2025
  

  Santen Pharmaceutical downgraded to hold from buy at Jefferies (¥1665.0000, 0)